Similar articles

• Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody.

  Sugiyama Y, Chen FA, Takita H, Bankert RB. Sugiyama Y, et al. Cancer Res. 1988 May 15;48(10):2768-73. Cancer Res. 1988. PMID: 3359438
• Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.

  Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K. Iwahashi T, et al. Cancer Res. 1993 Nov 15;53(22):5475-82. Cancer Res. 1993. PMID: 8106147
• Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.

  Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC Jr. Xu F, et al. Clin Cancer Res. 2000 Aug;6(8):3334-41. Clin Cancer Res. 2000. PMID: 10955821
• Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.

  Bodey B, Siegel SE, Kaiser HE. Bodey B, et al. Anticancer Res. 1996 Mar-Apr;16(2):661-74. Anticancer Res. 1996. PMID: 8687112 Review.
• Monoclonal antibodies in the treatment of lung cancer.

  Egri G, Takáts A. Egri G, et al. Eur J Surg Oncol. 2006 May;32(4):385-94. doi: 10.1016/j.ejso.2006.01.007. Epub 2006 Feb 28. Eur J Surg Oncol. 2006. PMID: 16504454 Review.